MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a single-institution, phase II study to determine the event-free survival at 1 year
post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related
donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the
biochemical correction of severe epidermolysis bullosa (EB).